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ABSTRACT
Our RNAseq analyses revealed that ZIP4 is a top gene up-regulated in more 
aggressive ovarian cancer cells. ZIP4’s role in cancer stem cells has not been reported 
in any type of cancer. In addition, the role and regulation of ZIP4, a zinc transporter, 
have been studied in the context of extracellular zinc transporting. Factors other 
than zinc with ZIP4 regulatory effects are essentially unknown. ZIP4 expression and 
its regulation in epithelial ovarian cancer cells was assessed by immunoblotting, 
quantitative PCR, or immunohistochemistry staining in human ovarian tissues. Cancer 
stem cell-related activities were examined to evaluate the role of ZIP4 in human high-
grade serous ovarian cancer cells in vitro and in vivo. RNAi and CRISPR techniques 
were used to knockdown or knockout ZIP4 and related genes. Ovarian cancer 
tissues overexpressed ZIP4 when compared with normal and benign tissues. ZIP4 
knockout significantly reduced several cancer stem cell-related activities in EOC cells, 
including proliferation, anoikis-resistance, colony-formation, spheroid-formation, 
drug-resistance, and side-population in vitro. ZIP4-expressing side-population highly 
expressed known CSC markers ALDH1 and OCT4. ZIP4 knockout dramatically reduced 
tumorigenesis and ZIP4 overexpression increased tumorigenesis in vivo. In addition, 
the ZIP4-expressing side-population had the tumor initiating activity. Moreover, the 
oncolipid lysophosphatic acid effectively up-regulated ZIP4 expression via the nuclear 
receptor peroxisome proliferator-activated receptor gamma and lysophosphatic 
acid ’s promoting effects in cancer stem cell-related activities in HGSOC cells was at 
least partially mediated by ZIP4 in an extracellular zinc-independent manner. Our 
critical data imply that ZIP4 is a new and important cancer stem cell regulator in 
ovarian cancer. Our data also provide an innovative interpretation for the apparent 
disconnection between low levels of zinc and up-regulation of ZIP4 in ovarian cancer 
tissues.
INTRODUCTION
Epithelial ovarian cancer (EOC) is the deadliest 
gynecologic cancer. The Cancer Genome Atlas(TCGA) 
data have set the genetic landscape of EOC [1]. We have 
developed a highly aggressive EOC cell line (ID8-P1) 
through in vivo passage of ID8-P0 cells in C57BL6 mice 
[2]. The tumor/ascites formation time is reduced from 
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~90 days for ID8-P0 cells to ~30 days in different ID8-P1 
cell lines isolated from tumors in different organs or from 
ascites [2]. RNAseq data in two independent pairs of 
ID8-P0 and ID8-P1 cells were obtained. Zip4 is among 
the genes highly up-regulated in ID8-P1 vs. ID8-P0 cells.
Intracellular zinc (Zn) homeostasis is tightly 
regulated under physiological conditions [3]. ZIP4 is one 
of the Zn transporters [4]. The regulation and activities of 
ZIP4 have been almost exclusively studied in the context 
of Zn [5–7]. ZIP4 plays tumor promoting roles in many 
cancer types, including pancreatic cancer, hepatocellular 
carcinomas, breast cancer, and glioma [8–10]. In contrast, 
Zn levels are significantly lower in prostate and ovarian 
cancer tissues, when compared to normal tissues [11] 
and Zn induces apoptosis in prostate and ovarian cancer 
cells [12, 13]. However, while ZIP4 expression is down-
regulated in prostate carcinoma and it has an inhibitory 
effect on prostate carcinoma cell proliferation and 
invasion, in an Zn-dependent manner,[8] ZIP4 is over-
expressed in EOC tissues,[14] and the role of ZIP4 in EOC 
has not been reported.
ZIP4 presents in the stem cell niche and intestine 
integrity [15], but has not been shown as a cancer stem 
cell (CSC) marker/gene in any cancer type. Our group 
was one of the earliest to identify EOC CSC [16–19]. 
Various CSC markers have been identified by different 
research groups, including CD44, CD117 (Kit), CD133, 
aldehyde dehydrogenase 1 (ALDH1), Oct4, EpCAM, 
Nanog, Nestin, and ABCG2 [16, 19–22]. Among the most 
consistent markers for EOC CSC are spheroid-formation 
and the side-population (SP) cells (capable of excluding 
Hoechst 33342 from cells), [23, 24] which have been 
shown to be an enriched source of CSC.
We were the first to show that the bioactive lipid 
molecule lysophosphatic acid (LPA) is a growth factor for 
EOC [25–28]. Responses to LPA are mediated primarily by 
their plasma membrane bound G-protein coupled receptors 
(LPAR1-6) [29, 30]. In addition, LPA has been identified as 
a ligand for the nuclear receptor peroxisome proliferator-
activated receptor gamma (PPARγ) [31, 32]. The LPA-
PPARγ studies are mainly limited to the vascular and 
metabolic processes [32]. During the course of this study, 
Seo et al. have shown that autotaxin (ATX) stimulates the 
maintenance of EOC stem cells through LPA-mediated 
autocrine mechanism [33]. LPAR1 and AKT1 are identified 
as the important down-stream signaling molecules 
mediating these effects in Seo’s work [33].
While our results are highly consistent to Seo’s work 
in supporting LPA’s CSC activity in EOC, a novel LPA-
PPARγ-ZIP4 and extracellular Zn-independent signaling 
pathway and its involvement in CSC has been revealed. 
Genetic, cell biological, and biochemical analyses were 
conducted in vitro and in vivo. CSC-related activities, 
including anoikis-resistance, drug-resistance, colony-
formation, spheroid-formation, side-population, and 
tumorigenesis were the central focuses of the work.
RESULTS
ZIP4 and other CSC markers in EOC were over-
expressed in human EOC tissues and in ID8-P1 
vs. ID8-P0 cells
The TCGA and Oncomine data suggest that the 
ZIP4 gene is over-expressed in EOC [14]. We confirmed 
the over-expression of ZIP4 in EOC using a subset 
of tissues obtained from CHTN, which we have used 
in our previous studies [34]. ZIP4 protein was over-
expressed in EOC vs. benign and normal ovarian tissues 
(Supplementary Figure 1; representative data). We also 
used an ovarian cancer TMA to evaluate ZIP4 expression. 
The results are summarized in Supplementary Table 1. 
Twelve (12) of 16 (75%) of HGSOC samples expressed 
high levels of ZIP4. The remaining (4 of 16) HGSOC 
tissues also expressed ZIP4, albeit with lower levels. 
Only 1 of 4 (25%) low grade serous ovarian cancer tissue 
samples expressed a high level of ZIP4 and none of other 
groups of tissues (ovarian endometrioid carcinoma, serous 
borderline ovarian cancer, and control tissues) expressed 
high levels of ZIP4. Representative results are shown in 
Supplementary Figure 2.
RNAseq analysis [35] of two independent pairs of 
ID8-P0 and ID8-P1 cells revealed more than 1,000 genes 
up-regulated in ID8-P1 vs. ID8-P0 cells, among which, 
up-regulation of more than 15 genes was confirmed by 
Western blot analysis, ELISA, and/or RT-qPCR in at least 
two human HGSOC cell lines, PE04 and OVCAR3, at 
the mRNA and/or protein levels (Table 1 and data to be 
published elsewhere). Interestingly, several previously 
identified EOC cancer stem cell (CSC) markers, including 
CD44, CD24, CD117 (Kit), and EpCAM, [16] were up-
regulated in ID8-P1 vs. ID8-P0 cells (Table 1). Several 
key signaling molecules involved in ID8 cells are also 
involved in the aggressiveness in human EOC cells as we 
showed previously [2]. ID8 cells may not fully recapitulate 
HGSOC characteristics, but the RNAseq data provided a 
guideline for potential functionally important genes. The 
majority of the work in this manuscript was conducted 
using human HGSOC cells.
LPA-dose and -time dependently up-regulated 
ZIP4 via PPARγ in EOC cells
Zip4 was shown to be 183-fold up-regulated in 
ID8-P1 vs. ID8-P0 cells in RNAseq data (Table 1). 
Here we confirmed ZIP4 overexpression in different 
ID8-P1 vs. ID8-P0 cells at the protein level (Figure 1A). 
Previously ZIP4 regulation had been exclusively studied 
in the context of Zn [7, 36]. The dramatic changes in 
ID8-P1 were only seen after cells were in vivo passaged, 
but not in vitro, strongly suggesting that the tumor 
microenvironment is important for these changes. We and 
others have shown that LPA is highly elevated in human 
EOC ascites [37], which represents an important part of 
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the EOC tumor microenvironment. LPA can be produced 
by either EOC tumor or stromal cells [38, 39]. Thus, 
we tested whether LPA could regulate ZIP4 expression. 
LPA up-regulated ZIP4 in ID8 and human HGSOC cells 
(PE01and OVCAR3), but not in a human ovarian surface 
epithelial (HOSE) cell line T29 in a time- and dose-
dependent manner (Figures 1B - 1F).
The majority of LPA’s known cellular effects are 
mediated by membrane GPCRs (LPAR1-6) [40]. In ID8-P0 
cells, a LPAR1/LPAR3 selective inhibitor Ki16425 did not 
inhibit LPA-induced ZIP4 expression. BrP-LPA, a dual 
inhibitor of pan-LPA receptor and autotaxin (ATX [41]) 
activity, increased the basal level of ZIP4 and blocked the 
increased ZIP4 expression induced by LPA, assessed by 
fold of increase (Figure 2A). Similar trend for Ki16425’s 
effect was observed in human HGSOC OVCAR3 and 
PE01 (Figures 2B - 2D). Figure 2D summarizes the fold 
changes observed in three independent experiments.
Different cell lines were used to show that the LPA-
induced ZIP4 expression was not limited to one cell line. 
Importantly, HGSOC cells were used in the majority of 
experiments described below to demonstrate the clinical 
relevance of the studies. Although certain cell line 
variations exist, which are common scientific observations, 
our results suggesting that LPAR1 and LPAR3 are unlikely 
to be involved in LPA-induced ZIP4 expression.
On the other hand, the PPARγ selective inhibitor 
GW9662 dose-dependently blocked the effect (Figures 
2A-2C), suggesting that LPA-induced ZIP4 was mainly 
mediated by PPARγ, and its GPCR receptors may be only 
partially involved. We used GW9662 under the conditions 
(concentration and treatment time) that major cell death 
was not apparent, evidenced and adjusted by actin loading 
and cell morphological observation. The inhibitor may 
also affect the basal level of ZIP4, but we focused on 
LPA-induced effect in this work. The Western analyses 
results from three independent experiments in PE01 cells 
are summarized in Figure 2D.
Compared to PE04 cells, PE01 cells expressed 
lower, but detectable levels of PPARγ, which was up-
regulated by LPA (Figure 2E). GW9662 may have 
other actions and may have off-targets. PPARγ has a 
broad range of biological activities and is regulated by 
complex mechanisms [41]. In this work, we focused only 
on whether it was involved in LPA-induced ZIP4 up-
regulation. To confirm the involvement of PPARγ in LPA-
ZIP4 induction, we generated PPARγ-KO clones in PE04 
cells using the Cas9 nuclease to facilitate RNA-guided 
site-specific DNA cleavage (CRISPR) system [42] (Figure 
2E). As shown in Figure 2F, lack of PPARγ expression 
completely blocked ZIP4 expression in these cells, 
suggesting that PPARγ is necessary for ZIP4 expression. 
LPA-induced ZIP4 expression was sensitive to both the 
transcription and translational inhibitors actinomycin D 
(ActD) and cyclohexylamine (CHX) in mouse and human 
EOC cells (Supplementary Figures 3A, 3B). In addition, 
we conducted quantitative PCR (Q-PCR) analyses and 
found that the time course of mRNA expression induced 
Table 1: Genes with altered expression in the more aggressive ID8-P1 vs. less aggressive ID8-P0 cells detected by 
RNAseq
Gene Fold (ID8-P1 vs. ID8-P0) Read in ID8-P1 P
Zip4 183 1174 3.20E-217
Piwil2 157 569 1.55E-117
Ncam1 6.2 2841 2.76E-73
Vegfa 7.5 11016 1.38E-68
Cyp27a1 9.9 545 1.92E-68
Kit (Cd117) 43 278 3.40E-53
Akt3 6.7 518 3.61E-47
Sox9 2.6 718 1.04E-26
Cd24a 7.7 130 2.10E-19
Ctnnb1 (β-catenin) 1.6 11249 5.02E-14
Epcam 4.9 91 1.13E-08
Abcc1 1.5 2762 2.91E-08
CD44 1.4 1426 8.31E-06
Reads in ID8-P1 cells reflect the relative RNA expression levels in EOC cells. Fold and Read values are averages of the two 
pairs of the samples. P values for the listed genes are all <10-5. The order of the genes listed is based on P values, with the 
smallest on the top.
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Figure 1: LPA-dose and -time dependently up-regulated ZIP4 via PPARγ in EOC cells. (A) ZIP4 expression in ID8-P0 and 
ID8-P1 cells from ascites (AS-P1) and peritoneal wall (PW-P1). The relative expression levels were quantified using the ratios of ZIP4/β-
actin (detected simultaneously in same blots using two colored fluorescence detection by the Li-Cor system as detailed in Supplementary 
materials) as shown in the figure. Five different ID8-P1 cell types (from different organs) were tested and all of them had elevated ZIP4. 
Only representative data are shown. (B-D) PE01, OVCAR3 and T29 cells were starved from serum for 16 hr prior to LPA (10 μM) 
treatment at different times as indicated. (E-F) PE01 and OVCAR3 were starved from serum for 16 hr prior to LPA treatment for different 
concentrations as indicated for 6 hr for PE01 and 16 hr for OVCAR3. The optimal LPA concentration and times to induce ZIP4 expression 
were 5-10 μM LPA and 2-6 hr for PE01 cells and 10 μM LPA and 16-24 hr for OVCAR3 cells. Representative results from ≥ three repetitive 
experiments are shown.
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by LPA (Supplementary Figures 3C, 3D) matched well 
to the protein levels in OVCAR3 and in PE01 cells 
(Figure 1), suggesting that ZIP4 was transcriptionally and 
translationally regulated.
ZIP4 was functionally involved in proliferation, 
anoikis-resistance, and colony-formation in EOC 
cells
To investigate the functions of ZIP4 in EOC, we 
generated ZIP4 knockdown (KD) or overexpression 
(OE) clones using shRNA against Zip4 in ID8 cells 
Figure 2: PPARγ was important for LPA induced ZIP4 up-regulation via in EOC cells. (A-C) ID8, OVCAR3 and PE01 
cells were starved from serum for 16 hr when the confluence was at ~80%. The cells were pre-treated with Ki16425 (10 μM), GW9662 (0.1 
to 1 μM), or BrP-LPA (10 μM prior to stimulation with LPA (10 μM) (D) Summery of three independent experiments conducted in PE01 
cells. (E-F) Human PE01 cell expressed lower level of PPARγ, which was up-regulated by LPA (10 μM). In PE04 cells, control-vector-
transfected and CRISPR PPARγ-KO single clones were seeded into 24-well plate (2x105 cells/ well) and cultured for 24 hr. Western-blot 
analyses were performed to examine the expression levels of PPARγ and ZIP4 in the presence or absence of LPA (10 μM) in PE01 and PE04 
cells. Representative results from ≥ three repetitive experiments are shown.
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(Figures 3A – 3B). We also established human PE04-
ZIP4-knockout (KO) clones using the CRISPR system 
and ZIP4-OE clones in human PE01 cells (Figures 3C – 
3D). ZIP4-KD or -KO reduced and ZIP4-OE increased 
cell proliferation in both mouse and human EOC cells 
(Figure 3E). In addition, both ID8-P1 and PE04 cells 
were sensitive to the PPARγ inhibitor GW9962 in cell 
proliferation (Figure 3F). Moreover, cell proliferation was 
reduced in PPARγ-KO clones (Figure 3G). ZIP4-KD or 
-KO also significantly reduced anoikis-resistance (Figure 
3H) and colony formation (Figure 3I) activities in EOC 
cells, supporting the importance of ZIP4 in EOC tumor 
promoting activities.
Most, if not all, of ZIP4’s cellular functions have 
been linked to its ability to transport Zn, with its other 
Zn-independent mechanisms essentially unknown. To 
address the paradoxical observation that EOC tissues 
had high ZIP4 expression, but inhibitory effects of Zn 
in EOC cells, we tested whether ZIP4 was functional in 
transporting extracellular Zn in EOC cells. Consistent to 
published data, extracellular Zn was toxic to EOC cells 
(Figure 3J). ZIP4-KO in PE04 cells reversed Zn toxicity in 
the range of 1 to 10 μM, suggesting that ZIP4 is functional 
in extracellular Zn transporting. However, all of our 
LPA-related experiments were conducted in the absence 
of serum and extracellular Zn. Thus, we detected novel 
extracellular Zn-independent functions and/or regulations 
of ZIP4 in EOC cells.
LPA and ZIP4 were involved in SP in EOC
Various CSC markers for EOC have been identified 
and the side-population (SP) cells are one of the most 
consistent markers for EOC CSC [16]. Using the 
Hoechst 33342 SP assays, we found that human EOC 
PE01 and OVCAR3 cells had ~ 3.8 and 1.6% cells in 
SP, respectively, which was inhibited by Verapamil (an 
inhibitor for drug efflux pump proteins and DNA-binding 
fluorophores that blocks SP), confirming that this is a real 
SP population. This SP population was increased to ~8.1% 
by LPA in PE01 cells (Figure 4A). LPA also increased the 
percent of SP in OVCAR3 cells by > 3-fold (Figure 4B).
Greater than 99% of SP in PE04 cells was CD44+ 
(a known EOC CSC marker) (Figure 4C). LPA shifted 
these cells to higher CD44 surface expression, without 
changing overall CD44 expression detected by cell 
staining (Figure 4C). In PE01 cells, CD44+CD117+ cells 
were low (~ 0.12%), which was increased by LPA to ~ 
0.87% in SP population (Supplementary Figure 4). In 
OVCAR3 cells, CD44+CD117+ cells were ~11.4%, which 
was increased by LPA to ~ 35.4% in SP population (Figure 
4D). Intriguingly, in the two ZIP4-KO clones (K36 and 
K37 in Figure 4E), the percent of SP reduced from 8.1 to 
2.37 and 1.08% in PE04 cells, respectively, supporting the 
important roles of ZIP4 in SP and CSC.
ZIP4 was involved in drug-resistance and 
spheroid-formation in EOC
Cis-platinum (CDDP) or other platinum compounds 
are the most commonly used chemo-reagents for EOC. 
We tested the potential roles of ZIP4 in drug-resistance. 
PE01 and PE04 cell lines are from the same patient before 
(PE01) and after (PE04) the onset of multidrug resistance 
to CDDP, chlorambucil, and 5-fluorouracil [43]. As 
expected, in vitro assays showed that PE04 was more 
resistant to CDDP than PE01 cells (Figure 5A). Over-
expression of ZIP4 PE01 cells increased resistance to 
CDDP and ZIP4-KO in PE04 cells reduced cell survival 
in the presence of CDDP, supporting the role of ZIP4 in 
DR, which has not been shown previously in any cells 
(Figures 5A and 5B). Similarly, ZIP4 was also involved in 
drug-resistance to DOX (Figure 5C).
Spheroids, in general, have high SP, drug-
resistance, and CSC activity [20]. Spheroids are present 
in the malignant ascites of essentially all EOC patients 
and represent a significant impediment to efficacious 
treatment due to their roles in progression, metastasis, and 
drug-resistance [44]. LPA has been shown recently to be 
potent spheroid inducer in EOC cells [33]. PE01, PE04, 
and OVCAR3 were all able to form spheroids using the 
stem cell culture conditions in suspension [19, 33]. The 
spheroid- formation was dependent on the cell density 
used (Figures 6A to 6B). Under the same conditions, 
PE04 cells formed more and/or larger spheroids than PE01 
(Figures 6C and 6D). LPA stimulated bigger spheroid 
formation in PE04 cells (Figure 6E).
We tested spheroid-formation in different ZIP4-
KO clones. ZIP4-KO had dramatic inhibitory effects on 
spheroid-formation. In Figure 6F, the top three panels 
show the representative spheroids formed in different 
fields in PE04 cells. Using the same conditions (104/
mL), ZIP4-KO clones did not have the capacities to form 
spheroids (the bottom 3 panels).
ZIP4 was involved in tumorigenesis and CSC 
activities in vivo
To further characterize the role of ZIP4 in SP cells, 
we separated SP and non-SP (FACS-sorted) in PE04 and 
OVCAR3 cells. Only SP cells formed spheroids and up-
regulation of known EOC stem cell markers Oct4 and 
ALDH1 (Figures 7A - 7C).
The i.p. injected PE04 control cells (vector-
transfected) developed tumors and ascites in 4-5 weeks 
in mice, with an average survival day of 31 (n=7, Figure 
8A). ZIP4-KO (combined K36 and K37 ZIP4-KO cells; 
mice n=5) dramatically reduced tumorigenesis and these 
mice had an average survival day of 62. Although tumors 
developed in each of the four ZIP4-KO cell injected 
mice, 2 of 5 developed ascites, compared to 4 of 7 in the 
control group. In addition, tumor numbers and sizes, as 
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Figure 3: ZIP4 was functionally involved in cell proliferation, anoikis-resistance, and colony formation in HGSOC 
cells. (A) LPA induced ZIP4 in ID8-P0 and ID8–P1 cells; ID8-P1-Zip4-KD clone was established using shRNA against Zip4. (B) ID8-P0 
ZIP4 over-expression (OE) cells. (C) PE01-ZIP4-OE cells. (D) ZIP4-KO clones (K36 and K37) in PE04 cells. (E) ZIP4-OE in either ID8 
or PE01 cells increased cell proliferation (48 hr to 72 hr) analyses using the MTT assays; conversely. ZIP4-KO in PE04 cells reduced cell 
proliferation. The proliferation was presented as fold changes normalized to vector-transfected PE01 cells (as one fold). (F) GW9662 dose-
dependently inhibited cell proliferation in ID8-P1 and PE04 cells. (G) PE04-PPARγ-KO clones (R2 and R3) reduced cell proliferation. 
(H) ZIP4-KD in ID8-P1 cells and –KO in PE04 cells reduced anoikis-resistance. (I) PE04-ZIP4–KO cellspresented a reduced colony-
formation. (J) Extracellular Zn induced cell death in PE04 cells; ZIP4-KO reduced Zn toxicity in the 1-10 μM range. Representative results 
from ≥ three repetitive experiments are shown. *P < 0.05; **P < 0.01; and ***P < 0.001.
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Figure 4: LPA and ZIP4 enhanced SP in HGSOC cells. (A-B) Under the conditions that ZIP4 expression was induced in PE01 and 
OVCAR3 cells, LPA treatment increased SP % ≥ 2 fold. (C) > 99% of PE04 SP cells were CD44 positive; LPA did not alter the percent of 
CD44+ cells, but increased cell surface expression in SP cells. (D) LPA increased the percentage of CD44+CD117+ cells in OVCAR3. Cells 
were starved in all LPA related experiments. (E) ZIP4-KO dramatically reduced SP % in PE04 cells. These cells were not starved from FBS 
when the FACS analyses were done. Representative results from ≥ three repetitive experiments are shown.
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well as metastatic sizes were significantly reduced in 
ZIP4 KO cell injected mice (Figures 8A – 8B). PE01 cells 
developed tumors much slower than PE04 cells. By 12 
weeks, only 1 of 4 mice with i.p. injected PE01 cells (5 x 
106) had developed tumors. In contrast, 4 of 4 mice with 
i.p. injected PE01-ZIP4-OE cells (5 x 106) had developed 
tumors and/or ascites (Figure 8A). Representative tumor 
nodules grew in the peritoneal walls and/or in the ovaries 
from WT, ZIP4-KO, ZIP4-OE cell injected mice are 
shown in Figure 8C.
Injection of only 500-5000 SP formed tumors in 8 
to 12 weeks (n=5 in total). In contrast, injection of up to 
5,000 non-SP cells did not formed tumors in 3 months 
(n=4), supporting the CSC properties of SP cells in EOC. 
Lack of ZIP4 expression in tumors derived from ZIP4 
KO cells was confirmed by IHC and tumors derived from 
wild-type PE04 cells had higher levels of proliferation as 
detected by the proliferative marker Ki67 (Figure 8D).
DISCUSSION
Our data presented here confirmed ZIP4 over-
expression in EOC tissues (Supplementary Figures 1-2) 
and support an innovative hypothesis that the apparent 
disconnection between Zn and ZIP4’s effects in EOC 
(as mentioned in the Introduction) is due to, at least in 
part, the fact that ZIP4 is able to mediate LPA’s tumor 
promoting activity in an extracellular Zn-independent 
manner. The novel regulation and signaling of the LPA-
ZIP4 axis provides paradigm-shifting concepts for studies 
in ZIP4 and possibly other solute transporting proteins. 
ZIP4 may represent as a prototype in this large family 
Figure 5: ZIP4 was involved in drug-resistance in HGSOC cells. (A) PE01-ZIP4-OE increased resistance to CDDP-induced cell 
death. (B-C) PE04-ZIP4-KO increased cell sensitivity to CDDP- and Dox-induced cell death.
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Figure 6: LPA and ZIP4 stimulated spheroid-formation in HGSOC cells. (A-B) PE04 and OVCAR3 cells were cultured in 
ultra-low-attachment plates; spheroid-formation was cell density dependent. Cells were cultured in stem cell conditions (see Methods for 
details) for 7 days. (C-D) Under the same conditions (1x104/mL in either 24- or 96-well plates), PE04 formed larger or more complete 
spheroids than PE01. (E) PE04 cells formed more complete spheroids under LPA treatment. (F) ZIP4-KO cells formed fewer and smaller 
spheroids when compared to control cells. The scale bars in D to I = 400 nm. Representative results from ≥ three repetitive experiments 
are shown.
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of proteins, for their solute transporting-independent 
signaling and regulatory mechanisms. The molecular 
mechanisms by which ZIP4 exerts its extracellular Zn-
independent signaling remain to be investigated.
This is the first report of ZIP4’s role in EOC. ZIP4 
stimulates cell proliferation, anoikis-resistance, stem cell-
related cellular activities (such as SP, spheroid formation, 
and CSC marker expression), and drug-resistance in vitro 
and tumor progression in vivo. In particular, the original 
choice of ZIP4 is from one of top candidate genes in 
highly aggressive and quickly progressed EOC cells vs. 
less aggressive EOC cells. Whether ZIP4 is involved 
in EOC grade, metastasis, recurrence, survival, and/or 
progression free survival in human tumors will be a highly 
interesting area to be further explored. Nevertheless, many 
genes/proteins have proven to be important cancer targets, 
even though they may not be involved in all steps of 
cancer progression.
Our in vitro and in vivo data provide the first lines of 
evidence that ZIP4 is likely to play crucial promoting roles 
in drug-resistance, SP, and CSC of HGSOC. In particular, 
ZIP4 strongly influences SP, spheroid formation, and in 
vivo tumorigenesis in HGSOC, which is consistent with 
its high expression in EOC tissues. These data suggest that 
ZIP4 is a novel target for EOC, with the LPA-PPARγ axis 
as one of its important up-stream regulators.
Seo et al have shown that autotaxin (ATX, the 
major LPA-producing enzyme) stimulates maintenance of 
EOC CSC through LPA- and LPAR1-mediated autocrine 
mechanisms in EOC cells [33]. While our data are highly 
consistent with LPA’s roles in EOC CSC as reported, the 
LPA-PPARγ-ZIP4 signaling pathway is novel, which has 
not been shown in any other cells. The majority of the 
data generated in Seo’s work used A2780 and SKOV3 cell 
lines, which are not HGSOC [45, 46]. It is possible that 
the LPA-PPARγ-ZIP4 pathway is cell line-dependent and/
or that LPAR- and PPARγ-mediated LPA effects co-exist 
in EOC cells.
The majority of published LPA biological effects are 
mediated by its plasma membrane LPAR1-6. All current 
LPA blocking strategies and clinical trials related to cancer 
focus on its membrane receptors (LPAR1-6) and on LPAR1-3 
Figure 7: ZIP4 increased CSC properties. (A). The two known EOC CSC markers, ALDH1 and OCT4 expressed at significantly 
higher levels in both OVCAR3 and PE04 SP vs. non-SP cells. ZIP4-KO in PE04 cells completely suppressed the high expression of these 
two genes in SP cells. (B) Only SP cells formed spheroids. When ZIP4 was KO in PE04 cells, even though SP cells could still be isolated 
using Hoechst-exclusion FACS, but these cells could not form spheroids. The SP portion and non-SP portion were separated by BD SORP 
FACSAria (BD Biosciences, San Jose, CA) after Hoechst-33342 Staining. 1×104 cells per well into Corning 24 Well Plate with low 
attachment surface under stem cell culture conditions. After 7 days in culture, the SP portion generated spheroids from the PE04/OVCAR3 
primary cells, but the non-SP portion cannot form any spheroid. (C) Similar results in spheroid-formation were observed in OVCAR3 SP 
and non-SP cells.
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Figure 8: ZIP4 was positively involved in tumorigenesis in vivo. (A-B) Summary of tumor and ascites development of the control 
(PE01 and PE04), PE01-ZIP4-OE, and PE04-ZIP4-KO cells injected into NSG mice (n=4-7 in each group). (C) Representative tumor 
pictures of tumors on the peritoneal wall and the ovary. (D) Representative immunostaining of ZIP4 and Ki67 (a proliferation marker) in 
the tumor sections derived from wild type and ZIP4 KO PE04 cells.
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more particularly [29]. At least three compounds blocking 
these receptors have passed phase I and phase II clinical 
trials [29]. While our Ki16425 data suggest that LPAR1 
and LPAR3 are unlikely to be involved in LPA-induced 
ZIP4 up-regulation, the results from BrP-LPA suggest that 
LPAR2,4-6 and/or ATX may be partially involved in non-
LPA related basal level ZIP4 regulation, which may be 
related to BrP-LPA’s off-targeting activities. This needs 
to be addressed using other approaches including genetic 
manipulations. Nevertheless, the current study is focused 
on the clear involvement of PPARγ in the LPA induced 
effect. Although LPA has been identified as a ligand 
for PPARγ [31, 47], the LPA-PPARγ studies are mainly 
limited to the vascular and metabolic processes [32, 48]. 
The roles of PPARγ-mediated LPA effects in cancer are 
essentially unknown.
PPARγ is a nuclear hormone receptor that mediates 
the effects of fatty acids and their derivatives at the 
transcriptional level [41]. HGSOC patients with a high 
expression level of PPARγ had significantly poorer overall 
survival [49]. Acyl-LPAs (only those with unsaturated 
fatty acid) bind PPARγ with affinities similar to that of 
the synthetic full agonist of PPARγ, rosiglitazone (Rosi), 
but their binding sites are different [49]. Interestingly, the 
biological effects of PPARγ may be ligand, cell type, and 
context-dependent. LPA and Rosi may induce similar or 
opposing effects in a cell context-dependent manner [32, 
50]. In addition, activating PPARγ by its other ligands 
appears to possess both pro- and anti-cancer activities. 
Even in the same cancer, such as colon and EOC, opposing 
results have been reported [32, 51–53]. The mechanisms 
underneath these paradoxical observations warrant 
additional investigation. Nevertheless, while our results do 
not completely rule out LPAR1-6-dependent actions, ZIP4’s 
regulation by LPA via PPARγ is a new finding, which 
suggest that co-targeting both groups of LPA receptors 
(GPCRs and PPARγ) is critical.
PPARγ plays an important role in stroke, 
cardiovascular, age-related macular degeneration, and 
other inflammation-related diseases. PPARγ agonists (not 
antagonists or inhibitors) confer benefits in diabetes and 
atherosclerosis, two known risk factors associated with 
cardiovascular disease. However, deleterious effects 
have limited their clinical usages [54–56]. Since chronic 
inflammation is a well-known factor closely associated 
with cancer [57, 58], and PPARγ activation by synthetic 
agonists will preferentially bind with retinoid X receptor 
α and signal antiproliferative, antiangiogenic, and 
prodifferentiation pathways in several tissue types, these 
agonists have been tested for their anti-cancer effects. 
Thiazolidinediones (TZDs) are PPARγ agonists and 
orally effective medicines for metabolic syndrome and 
type 2 diabetes. Although data from human trials suggest 
the efficacy of TZDs as monotherapy in prostate cancer 
and glioma and as chemopreventive agents in colon, 
lung, and breast cancer, the action of TZDs are highly 
complex and those actions do not correlate with cellular 
PPARγ expression status and/or activation [59, 60]. Our 
results also imply that different agonist types may induce 
distinct effects, suggesting these issues require significant 
additional investigation before successful PPARγ targeting 
in clinical settings.
The regulation and activities of ZIP4, an important 
Zn transporter, have been exclusively studied in the 
context of Zn [6, 36, 61]. The ZIP4 promoter has only 
been minimally studied in mouse brain tissue and mouse 
intestinal epithelial cells [62]. Initial search in the 2.3 kb 
ZIP4 promoter region did not identify a classical PPARγ-
cis element. This suggests either longer promoter regions 
or other elements need to be examined, or an indirect 
PPARγ effect is involved.
Our preliminary data suggest that PE01 (or PE04) 
and OVCAR3 cells may have differential epigenetic 
regulations [e.g. trichostatin A, an inhibitor of histone 
deacetylase (HDAC) families of enzymes, did not affect 
LPA-induced ZIP4 in PE01 cells but blocked this action 
in OVCAR3 cells; our unpublished observations). These 
additional layers of regulation may affect the optimal time 
of LPA-induced ZIP4. In addition, we found that ZIP4 
expression could be stress stimulated. Cell starvation 
appears to have regulatory effect on ZIP4, and hence the 
basal levels of ZIP4 during starvation may change as we 
observed in Figure 1. Moreover, ZIP4 appeared to be 
doublets in ID8 cells in Western blots detected by a mouse 
anti-ZIP4 antibody, but the human ZIP4 antibody (cross-
react with mouse ZIP4) detected ZIP4 as a single band. 
These aspects warrant further investigation.
Taken together, we have revealed an innovative 
LPA-PPAR-ZIP4 signaling pathway and provide strong 
data to support ZIP4’s tumor promoting activities in EOC, 
and in human HGSOC cells in particular. Importantly, 
ZIP4 plays pivotal promoting roles in EOC CSC, which 
are the critical target for EOC treatment.
MATERIALS AND METHODS
Reagents, cell lines and culture
Oleoyl-LPA was from Avanti Polar Lipids 
(Birmingham, AL). The following reagents were used: 
Ki16425 (Calbiochem, San Diego, CA); BrP-LPA (EBI, 
Salt Lake City, UT); C3 exoenzyme (Cytoskeleton, 
Denver, CO); GW9662 (EMD Corp; Billerica, MA); 
and actinomycin D (ActD) and cyclohexamide (CHX; 
Sigma-Aldrich, St. Louis, MO). Alexa fluor-conjugated 
secondary antibodies were from Life Technologies (Grand 
Island, NY). Mouse ZIP4 antibody (AF7315) was from 
R&D Systems (Minneapolis, MN). Human ZIP4 (20625-I-
AP) and PPARγ (H100) antibodies were from Proteintech 
(Rosemont, IL) and Santa Cruz (Paso Robles, CA). Mouse 
ZIP4 antibody was from Santa Cruz (Paso Robles, CA). 
The pair of PE01/PE04 cell lines was from Dr. Daniela 
Matei (Northwestern University); the OVCAR3 cells were 
obtained from ATCC (Manassas, VA). The ID8, T29, and 
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OVCA433 cell lines were kind gifts from Dr. R. Bast 
(M.D Anderson), Dr. Jinsong Liu (M.D Anderson), and Dr. 
Paul F Terranova (University of Kansas Medical Center), 
respectively. These cell lines were authenticated by ATCC. 
ID8-P1 cells were obtained as we published previously 
[2]. In brief, ID8-P0 cells (5×106) were injected into the 
peritoneal cavity of C57-BL6 mice. Between 80 and 
85 days post injection, tumor nodules on the peritoneal 
wall were isolated and cultured with Zeocin (100 μg/
mL) to select tumor cells. The new cell lines were termed 
ID8-P1. All cell lines were maintained in a humidified 
atmosphere at 37°C with 5% CO2. OVCAR3 cells were 
maintained in RPMI-1640 supplemented with 20% FBS 
(ATCC, Manassas, VA), 0.01 mg/mL insulin and 50 U/mL 
penicillin, and 50 μg/mL streptomycin. PE01/PE04 cells 
were cultured in RPMI 1640 with glutamine, 10% FBS, 
and 100 μg/mL Penicillin-Streptomycin-Amphotericin 
B. For serum starvation, cells were incubated in the basal 
medium without FBS or antibiotics. LPA treatment was 
performed in cells starved from serum for 16-24 hr.
RNA-sequencing analysis and stable clones
Stranded whole transcriptome RNA-seq was 
performed as we have described [35]. Briefly, biological 
duplicates of cells (107) were lysed and RNA was 
extracted according to manufacturer’s protocol (Qiagen 
RNeasy Mini kit). Total RNA was fractionated by size 
using ethanol concentration manipulations. The large 
RNA fraction (>200 nt) was fragmented prior to library 
construction. Ribosomal RNA was reduced by duplex 
specific nuclease (DSN) following limited hybridizations 
of both fractions and then amplified to add barcodes 
for multiplexing on the Illumina HiSeq2000 platform. 
Demultiplexing was performed by CASAVA v1.8.2 and 
trimming was accomplished with Trimmomatic v0.22 
with additional trimming by fastx_clipper v0.0.13.2. Read 
mapping was performed by tophat2 v2.0.6 to the human 
genome hg19 (UCSC) with Gencode annotation v13 
allowing no more than two mismatches. ZIP4 and PPARr 
CRISPR lentiVirus vectors (GeneCopoeia, Rockville, MD) 
were used for gene knockout transfected to 293T cells for 
virus packaging. PE01/PE04 and OVCAR3 cells were 
infected by virus 3 times and stable clones were selected 
by puromycin (0.5 μg/mL). More details of the methods 
are described in Supplementary Materials.
Western blot analysis
Western blot analyses were conducted using 
standard procedures and proteins were detected using 
primary antibodies and fluorescent secondary antibodies 
(IRDye 800CW-conjugated or IRDye 680-conjugated 
anti-species IgG, Li-Cor Biosciences, Lincoln, NE) as 
we described previously [2]. The fluorescent signals were 
captured on an Odyssey Infrared Imaging System (Li-
Cor Biosciences, Lincoln, NE) with both 700- and 800-
nm channels. Boxes were manually placed around each 
band of interest, and the software returned near-infrared 
fluorescent values of raw intensity with background 
subtraction (Odyssey 3.0 analytical software, Li-Cor 
Biosciences, Lincoln, NE). The protein MW marker used 
was the Pre-stained SDS-PAGE Standards, broad range 
(BIO-RAD, Cat. Log # 161-0318).
Cell proliferation, anoikis-resistance, and 
spheroid-formation assays
Cell (2×103) were cultivated in tissue culture 96-well 
plates (TPP, Switzerland in Europe) in growth medium, 
cultured for 48 hr, 10 μl of the MTT dye solution (Sigma, 
USA) (5 mg/ml in phosphate buffer saline) was added to 
the cells; the cells were incubated at the same conditions 
for 3 hr. The supernatant was removed after centrifugation 
(1500 rpm, 5 min), 100 μl of dimethyl sulfoxide was 
added to each well to dissolve formazan. The absorption 
was measured by a Multilabel Counter (VICTOR3, 
Perkin Elmer, USA) at a wavelength of 540 nm. At 
least three independent experiments were conducted. In 
each experiment set, the same cell numbers were seeded 
for control and all testing cell lines with 3-8 wells/data 
point. The mean absorption values at 540 nm from the 
control cells were used as one fold in each figure and the 
proliferation results from testing cell lines were presented 
as fold changes of the absorption values when compared 
to that of the control cells. Anoikis-resistance and soft 
agar colony assays were described in detail previously [2]. 
Single cells were re-suspended at 1x103 to 1x105 cells/mL 
in serum-free DMEM/F12 supplemented with 5 μg/mL 
insulin (Sigma), 20 ng/mL human recombinant epidermal 
growth factor (EGF; Invitrogen), 10 ng/mL basic fibroblast 
growth factor (bFGF; Invitrogen), and 0.4% bovine serum 
albumin (BSA; Sigma), followed by culturing in 24- or 
96-well Ultra Low Attachment plates (Corning, NY). 
Spheroids were photographed after seven days in culture.
Quantitative real-time PCR
RNA was extracted with the RNeasy mini kit 
(Qiagen, Valencia, CA) and reverse transcribed by 
M-MLV reverse transcriptase. Quantitative real-time 
PCR was performed on a Light Cycler 480 (Roche, 
Indianapolis, IN) with a SYBR Green I Master Mix 
(Roche, Indianapolis, IN). mRNA abundance was 
normalized to GAPDH. Negative controls contained no 
reverse transcription or the reverse transcriptase. RNAs 
from triplicate cell pellets per condition were analyzed. 
Relative gene expression was calculated using the 
method given in Applied Biosystems User Bulletin No.2 
(P/N 4303859B). Primer pairs used in this study were: 
GAPDH: F, 5’-CACCATTGGCAATGAGCGGTTC-
3’/R, 5’-AGGTCTTTGCGGATGTCCACGT-3’; 
ZIP4: F, 5’-ATGTCAGGAGCGGGTCTTGC-3’/ 
R, 5’- GCTGCTGTGCTGCTGGAAC-3’. ALDH1: 
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F, 5’- CTGCTGGCGACAATGGAGT-3’/R, 5’- 
GTCAGCCCAACCTGCACAG-3’; Oct4: F, 
5’- TCAGGTTGGACTGGGCCTAGT-3’/R, 5’- 
GGAGGTTCCCTCTGAGTTGCTT-3’.
FACS side-population (SP) analyses
Starved cells (5×105) were treated with LPA under 
the ZIP4-induction conditions. Cells were detected 
by acutase and trypsin and re-suspended in DMEM+ 
(DMEM+10 μM HEPES + 2% FBS). Verapamil (10 μM, 
37° C for 30 min) was used in control assays to ensure 
that the gated SP populations were indeed SP. Hoechst 
3442 (5 μg/mL) was added and cells were incubated at 
37° C for 90 min. After centrifugation at 2200 rpm for 
5 min, cells were re-suspended in Cold HBSS+ buffer 
(Hanks’ Balanced Salt Solution +10 μM HEPES + 2% 
FBS; 106 cells/ mL). Labeling CD44 and/or CD117 was 
conducted at 4° C for 30 min. Cells were re-suspended 
at 2×106 cells/mL in ice cold HBSS+ and the FACS 
analyses were conducted in BD SORP FACSAria 
(BD Biosciences, San Jose, CA) for SP sorting and 
analysis and BD LSR Fortessa (4 laser) Analyser (BD 
Biosciences, San Jose, CA) for surface marker analysis 
(CD44/CD117).
Human tissue immunohistochemistry
Normal ovary, benign ovary, and ovarian cancer 
tissues were purchased from the Cooperative Human 
Tissue Network (CHTN; Philadelphia, PA); the usage 
of these tissues was approved by an Indiana University 
School of Medicine IRB as described previously [34]. 
Standard IHC procedures were used. A tissue microarray 
containing ovarian high-grade serous carcinoma in 
triplicate 1.0-mm cores, along with other gynecological 
neoplasms and controls, was constructed using de-
identified samples from patients whose cases were 
reviewed by the Johns Hopkins Department of Pathology. 
Construction was performed by the Oncology Tissue 
Services at Johns Hopkins University. Institutional Review 
Board approval was obtained for this study cohort.
Xenograft mouse model
Female NSG mice were obtained from the In Vivo 
Therapeutics Core, Indiana University School of Medicine 
(Indianapolis, IN). At 7 to 10 weeks of age, PE01 or 
PE04 cells [Vector-transfected control, ZIP4-KO, ZIP4-
overexpression (OE), or PPARγ-KO, 5×102 to 5×106 in 
500 μL of PBS] were i.p. injected into mice. Tumors 
were monitored daily. Mice were euthanized after tumor 
and ascites development. Tumors were counted at each 
metastatic location, and tumor diameters were measured. 
Animal protocols were approved by the Indiana University 
School of Medicine Animal Care and Use Committee.
Statistical analyses
The Student’s t-test was utilized to assess the 
statistical significance of the difference between two 
treatments. The asterisk rating system as well as quoting 
the P value in this study was * P < 0.05; ** P < 0.01; and 
*** P < 0.001. A P value of less than 0.05 was considered 
significant.
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